Otonomy Reports Corporate and Product Pipeline Update

Back to Jobs

Multiple clinical trial readouts for OTO-313 in tinnitus and OTO-413 in hearing loss  expected during 2022 Current capital funds operations into second half of 2023 SAN DIEGO , Jan. 06, 2022 (GLOBE NEWSWIRE) — Otonomy , Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development

Apply Now